Imperva to Be Acquired by Investment Firm Thoma Bravo for $2.1 Billion
Nasdaq-listed Imperva will delist and operate as a privately-held company under its current administrative team if the deal goes through
For daily updates, subscribe to our newsletter by clicking here.On Nasdaq’s Tuesday’s market close, Israel-based Imperva stood at $43.06 per share. Following the announcement, Imperva closed Wednesday at $55.11, a 28% increase.
The Redwood City, California-headquartered company originally founded in Israel develops and sells information security software for databases and web apps. It currently employs 400-500 people in Israel in two research and development centers.
Imperva listed on Nasdaq in 2011 at a company value of $400 million. In 2016, Elliott Associates LP, a unit of activist hedge fund Elliott Management Corporation, disclosed a 9.8% stake in the company, stating it believes it is “materially undervalued.” Elliott pushed for far-reaching changes in the company, including layoffs, resulting in nine executives leaving Imperva one after another, among them the company’s Israeli co-founders and its CEO. Elliott has since offloaded some of its stock, holding on to a stake of around 5%.
The last quarter of 2017 was Imperva’s first quarter to report profitability. While the company reported a $23.1 million GAAP net loss for the second quarter of 2018, on Wednesday it announced that based on preliminary financial information, it expects total revenues in the range of $90 million to $92 million in the third quarter, above analysts’ expectations.
According to Wednesday’s release, Imperva will delist and operate as a privately-held company under its current administrative team if the deal goes through. Thoma Bravo which manages over $30 billion in assets, already holds several cyber companies including DigiCert Inc. and Bomgar Corp.
The acquisition will enable Imperva to better focus on developing some of its more innovative technologies, Imperva co-founder Amichai Shulman told Calcalist in an interview. Shulman, who still holds a stake in the company, was Imperva’s chief technology officer and then its chief scientist. He left the company early in 2018. It’s hard for a public company to be innovative as it must deliver financial results each quarter, and so the deal could bolster Imperva, Shulman said, adding that he hopes Thoma Bravo “is not looking to make a quick buck but create real value.”
Shulman estimated the fund is acquiring the company now “because it thinks that with a not-too-large investment, it could make Imperva more successful quickly. Sometimes, it’s easy for a private company to shoot up again.”